ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: Finally, a German expert consensus panel recommended initiating treatment with 30 mg/d in patients with CP-CML without ABL kinase domain mutations, resistant to only one TKI, with a good response status, intolerant to TKI despite a good response, and with increased cardiovascular risk.55